Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17713492 | 0.88 | PYCR1 (0.39) | DPP4PYCR1DGAT1 | |
| SCHEMBL17713324 | 0.78 | PYCR1 (0.39) | PYCR1 | |
| SCHEMBL2794279 | 0.76 | MPO (0.43) | DPP4PYCR1POLB | |
| SCHEMBL17713434 | 0.75 | DPP4 (0.37) | DPP4 | |
| SCHEMBL17713426 | 0.75 | NAAA (0.36) | DPP4 | |
| SCHEMBL18600051 | 0.75 | CHEK1 (0.42) | DPP4PYCR1DGAT1POLB | |
| SCHEMBL16064312 | 0.74 | PYCR1 (0.41) | DPP4PYCR1DGAT1 | |
| SCHEMBL29809175 | 0.74 | PYCR1 (0.41) | DPP4PYCR1DGAT1 | |
| SCHEMBL16043165 | 0.74 | PYCR1 (0.41) | DPP4PYCR1DGAT1 | |
| SCHEMBL5041752 | 0.74 | TAAR1 (0.50) | DPP4DGAT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9901571-B2 | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-10-26 | — | — | US | disclosed |
| EP-3212648-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc. (JP) | 2017-09-06 | — | — | EP | disclosed |
| CN-106795158-A | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists | 拉夸里亚创药株式会社 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016067638-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304277-A1 | TETRAHYDROPYRAZOLOPYRIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | DPP4 851/4885PYCR1 845/4885DGAT1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.